Showing 1511-1520 of 2314 results for "".
- Opus Genetics Doses First Pediatric Patient in Phase 1/2 Trial for OPGx-LCA5 Gene Therapyhttps://modernod.com/news/opus-genetics-doses-first-pediatric-patient-in-phase-12-trial-for-opgx-lca5-gene-therapy/2482675/Opus Genetics announced the first pediatric patient has been dosed in its ongoing phase 1/2 clinical trial evaluating OPGx-LCA5, its investigational gene therapy for Leber congenital amaurosis (LCA). Initial data from the pediatric cohort is expected to be shared by Q3
- FDA Expands Label for Izervay for GA Allowing for No Limitation on Duration of Dosinghttps://modernod.com/news/fda-expands-label-for-izervay-for-ga-allowing-for-no-limitation-on-duration-of-dosing/2482665/The FDA has approved an expanded label for Astellas Pharma's geographic atrophy drug Izervay (avacincaptad pegol intravitreal solution), allowing the drug to be used without a limitation on duration of dosing. The approval, which provides physicians and pat
- Prevent Blindness Receives Legacy Donation of $9.7 Million, Largest in Historyhttps://modernod.com/news/prevent-blindness-receives-legacy-donation-97-million-largest-in-history/2482622/Prevent Blindness announced it has received a donation of $9.7 million from the Estate of Pamela Behrens, a Florida resident and previous donor. Founded in 1908, this is the largest donation the organization has ever received. Ms. Behrens made the donation in honor of her late hus
- Atsena Completes Dosing in Part A of Phase 1/2 Trial Evaluating Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-completes-dosing-in-part-a-of-phase-12-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482579/Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.S
- Sepul Bio Announces First Patient Dosed in Trial Using Ultevursen for RPhttps://modernod.com/news/sepul-bio-annouces-dosage-of-first-participant-in-clinical-trial-using-ultevursen-for-retinitis-pigmentosa-treatment/2482578/Sepul Bio announced the first person has been dosed for the LUNA clinical study, a phase 2b trial using ultevursen for USH2A-associated retinitis pigmentosa (RP). USH2A, or Usher Syndrome type 2a, is the most common cause of autosomal recessive retinitis pigmentosa that affec
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves
- EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy Duravyuhttps://modernod.com/news/eyepoint-pharmaceuticals-doses-first-patient-in-phase-3-lugano-trial-for-wet-amd-therapy-duravyu/2482512/EyePoint Pharmaceuticals announced dosing of the first patient in its phase 3 LUGANO clinical trial of Duravyu. This investigational sustained delivery therapy, formerly known as EYP-1901, aims to treat wet age-related macular degeneration (AMD) using a patent-protected formulation of vorolanib,
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300
- Claes H. Dohlman, MD, Cornea Research Pioneer and Visionary, Passes Away at 101https://modernod.com/news/claes-h-dohlman-md-cornea-research-pioneer-and-visionary-passes-away-at-101/2482356/Cornea Research Pioneer Claes H. Dohlman, MD, PhD, professor of Ophthalmology, Emeritus, and former Chief and Chair of the Department of Ophthalmology at Mass Eye and Ear and Harvard Medical School (HMS), passed away at the age of 101 on July 14, 2024, Mass Eye and Ear announced on Monday.
- Ocugen Doses First Patient in Phase 3 Clinical Trial for OCU400 Gene Therapy for RPhttps://modernod.com/news/ocugen-doses-first-patient-in-phase-3-clinical-trial-for-ocu400-gene-therapy-for-retinitis-pigmentosa/2482326/Ocugen announced that the first patient has been dosed in its phase 3 liMeliGhT clinical trial for OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a one-